絞り込み

16636

広告

Safety Outcomes of Apixaban Compared With Warfarin in Patients With End-Stage Renal Disease.

著者 Sarratt SC , Nesbit R , Moye R
Ann Pharmacother.2017 Jun ; 51(6):445-450.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (242view , 0users)

Full Text Sources

Medical

Miscellaneous

Current guidelines make no specific recommendations on the selection of direct oral anticoagulants for the prevention and treatment of venous thromboembolism in patients with end-stage renal disease (ESRD) receiving hemodialysis. Based on these guidelines, warfarin remains the anticoagulant of choice in these patients.
PMID: 28478715 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード